Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions

This study discusses the characteristics and workings of CD24/Siglec-10-targeted immunotherapy and offers a summary of current advances in CD24/Siglec-10-related immunotherapy research for cancer. We then suggested potential directions for CD24-targeted immunotherapy, basing our speculation mostly on the results of recent preclinical and clinical trials.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research